Osprey Medical share price shoots 8% higher after product approval

The Osprey Medical Inc (ASX: OSP) share price is up by almost 9% today after the company received important CE approval out of Europe.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Osprey Medical Inc (ASX: OSP) share price is today surging higher after it was announced that the company has received European CE Marking approval for its core European product.

At the time of writing, the Osprey Medical share price is up 8.57% to 3.8 cents.

What Osprey Medical does

Osprey Medical aims to make heart imaging procedures safer for patients with poor kidney function. The company's core technologies originated from research conducted by Dr David Kaye at Melbourne's Baker Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimise dye usage and monitor the dose levels of dye real time throughout the procedure.

Osprey's flagship product is its DyeVert system. The company recently announced a strategic alliance with US giant GE Healthcare to distribute the product.

What does the approval mean?

The CE Marking approval for its DyeVert Power XT device means the product can now be marketed and sold across Europe. Europe is a core market for Osprey and a significant player in the global power injector market. The DyeVert Power XT device is expected to form a core product in the portfolio that is being commercialised by GE Healthcare.

Osprey Medical president and CEO, Mike McCormick commented: "We are delighted to have received CE Mark approval for our Power XT device."

"The approval was a critical building block in our European roll-out and the timing is perfect, following the strategic alliance formed with GE Healthcare in July," he added.

Clinical and operations update

In addition to the CE market approval, an important peer-reviewed manuscript was published by Dr Carlo Briguori. This study further validates the effectiveness of Osprey's DyeVert technology at improving patient outcomes and lowering hospital cost.

The Osprey Medical share price was also driven higher following an update on the partnership with GE Healthcare. Osprey has confirmed the agreement is expected to contribute materially to Osprey's revenue over the 4-year contracted period. The deal also aids increased diversification for the company as it adds to the company's sales outside the US. Under the agreement, Osprey's products will be distributed across Europe, Russia, the Middle East, Africa, Central Asia and Turkey.

Foolish takeaway

The Osprey Medical share price has been on a tear since the announcement of its agreement with GE Healthcare and is currently up 280% since its lows in late July. However, the company is still suffering at the hands of COVID-19 and seeing material declines in sales revenues. Despite this, Osprey is still poised for growth, as the deal is forecast to add 40% in revenue by 2024.

Motley Fool contributor Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Excited group of friends sitting on sofa watching sports on TV and celebrating.
Healthcare Shares

Guess which ASX 200 stock is jumping 16% on big news

Let's find out what news is getting investors excited this afternoon.

Read more »

A man slumps crankily over his morning coffee as it pours with rain outside.
Healthcare Shares

Why is this ASX 300 stock crashing 18% today?

Investors are rushing to the exits. But why? Let's look into things.

Read more »

Health professional working on his laptop.
Healthcare Shares

Are CSL shares at risk from the Trump tariffs?

How exposed are CSL shares to potential Trump medicinal tariffs?

Read more »

Donor donates blood in medical clinic. Beautiful European woman of 30 years sits in medical chair looking into camera and smiling.
Healthcare Shares

What did CSL have to say at Macquarie's 2025 conference?

Does this business have a healthy growth outlook?

Read more »

smiling health care workers in a medical setting
Healthcare Shares

Sonic Healthcare shares are down more than 40% since 2021. Will its AI initiative be the catalyst for a turnaround?

Could AI spark a recovery for this ASX healthcare stock?

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Why is this ASX All Ords stock jumping 7% today?

This stock is ending the week strongly. Let's find out what is getting investors excited.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Why is this ASX 200 stock crashing 30% today?

What's going with this stock? Let's find out why its shares are deep in the red.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 114% in a year, why is the Pro Medicus share price leaping higher again on Thursday?

Pro Medicus shares are back in form today and leaping ahead. Here’s why.

Read more »